Dr. Spivak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287Phone+1 410-955-3142
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1969 - 1972
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1968 - 1969
- Johns Hopkins UniversityResidency, Internal Medicine, 1965 - 1966
- Johns Hopkins University School of MedicineInternship, Transitional Year, 1964 - 1965
- Weill Cornell MedicineClass of 1964
Certifications & Licensure
- MD State Medical License 1969 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Research Tissue Bank Start of enrollment: 2007 Sep 01
- Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
- Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Publications & Presentations
PubMed
- 19 citationsCould Hypoxia increase the prevalence of thrombotic complications in Polycythemia VeraMaurizio Zangari, Louis Fink, Giulia Tolomelli, Jasmine C.H. Lee, Brady L. Stein
Blood Coagulation & Fibrinolysis. 2013-04-01 - 69 citationsHydroxycarbamide: a user's guide for chronic myeloproliferative disorders.Jerry L. Spivak, Hans Carl Hasselbalch
Expert Review of Anticancer Therapy. 2011-03-01 - 40 citationsMyeloproliferative Neoplasms.Jerry L Spivak
The New England Journal of Medicine. 2017-06-01
Abstracts/Posters
- Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational BurdenJerry L. Spivak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine ModelsJerry L. Spivak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- High Mobility Group A1 Chromatin Regulators: Key Epigenetic Switches and Therapeutic Targets Required for Leukemic Transformation in JAK2 Mutant MPNJerry L. Spivak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- High Mobility Group A1 Chromatin Remodeling Proteins Amplify Inflammatory Networks to Drive Leukemic Transformation in Chronic Myeloproliferative Neoplasia in Humans a...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Independent Association of Male Sex with Presentation and Clinical Outcomes in Myeloproliferative Neoplasms2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- COVID Vaccine Dystopia: A Manifesto Pt. 2 (By Dr. Joel S. Hirschhorn)December 2nd, 2021
- Reader Responses: Is JAK2 Positivity Clinically Significant in This 28-Year-Old Patient with Budd-Chiari Syndrome?September 1st, 2021
- Covid-19 Injections: What the Officials Are SayingFebruary 11th, 2021
- Join now to see all
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/jerry-spivak
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: